Status: Not yet recruiting
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are: * Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797? Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Participants needed: 22
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Aug 11, 2026Locations: 1
Eligibility criteria
Age ≥18 years at the time of consent [+9]
Excluded Diagnoses: Primary Myelofibrosis in the dose escalation phase and could...